Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
TransMedics Group Inc (TMDX)
NASDAQ:TMDX
Holding TMDX?
Track your performance easily
TMDX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$68.84 - $177.37
Previous Close$86.71
Volume1.03M
Average Volume (3M)1.64M
Market Cap
$2.91B
Enterprise Value$3.10B
Total Cash (Recent Filing)$330.10M
Total Debt (Recent Filing)$518.15M
Price to Earnings (P/E)92.9
Beta1.91
Next Earnings
Mar 04, 2025EPS Estimate
$0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.93
Shares Outstanding33,561,517
10 Day Avg. Volume1,686,234
30 Day Avg. Volume1,638,525
Standard Deviation0.26
R-Squared0.17
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)12.35
Price to Sales (P/S)6.94
Price to Cash Flow (P/CF)101.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.72
Enterprise Value/Gross Profit20.11
Enterprise Value/Ebitda50.65
Forecast
1Y Price Target
$116.00Price Target Upside33.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
TransMedics Group News
Bulls Say, Bears Say
Bulls Say
Growth PotentialTransMedics still delivered +64% year-over-year growth (+76% US growth) and reiterated the FY24 guidance, noting challenges were more transient and didn't stem from share loss or pricing pressure.
Market PositionTMDX remains the market leader in a still very underpenetrated market.
Revenue OutlookManagement raised its 2024 revenue guidance significantly after delivering a strong first half performance.
Bears Say
Financial PerformanceTransMedics reported Q3 revenue of $108.8M, missing the $118.6M estimate and consensus of $115.0M.
Growth Concerns2025 consensus estimates are likely too high and expect further downward revisions.
Market CompetitionTMDX is facing intensifying competition from a variety of directions including OrganOx, Paragonix Technologies, and normothermic regional perfusion.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
TMDX FAQ
What was TransMedics Group Inc’s price range in the past 12 months?
TransMedics Group Inc lowest stock price was $68.84 and its highest was $177.37 in the past 12 months.
What is TransMedics Group Inc’s market cap?
Currently, no data Available
When is TransMedics Group Inc’s upcoming earnings report date?
TransMedics Group Inc’s upcoming earnings report date is Mar 04, 2025 which is in 69 days.
How were TransMedics Group Inc’s earnings last quarter?
TransMedics Group Inc released its earnings results on Oct 28, 2024. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.293 by -$0.173.
Is TransMedics Group Inc overvalued?
According to Wall Street analysts TransMedics Group Inc’s price is currently Undervalued.
Does TransMedics Group Inc pay dividends?
TransMedics Group Inc does not currently pay dividends.
What is TransMedics Group Inc’s EPS estimate?
TransMedics Group Inc’s EPS estimate is $0.17.
How many shares outstanding does TransMedics Group Inc have?
TransMedics Group Inc has 33,561,516 shares outstanding.
What happened to TransMedics Group Inc’s price movement after its last earnings report?
TransMedics Group Inc reported an EPS of $0.12 in its last earnings report, missing expectations of $0.293. Following the earnings report the stock price went down -29.895%.
Which hedge fund is a major shareholder of TransMedics Group Inc?
Among the largest hedge funds holding TransMedics Group Inc’s share is Driehaus Capital Management LLC. It holds TransMedics Group Inc’s shares valued at 226M.
---
Company Description
TransMedics Group Inc
TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.
---
TMDX Earnings Call
Q3 2024
0:00 / 0:00
---
TMDX Stock 12 Month Forecast
Average Price Target
$116.00
▲(33.78% Upside)
Technical Analysis
Best Analysts Covering TMDX
1 Year
1 Year Success Rate
18/25 ratings generated profit
1 Year Average Return
+39.26%
reiterated a buy rating last month
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 72.00% of your transactions generating a profit, with an average return of +39.26% per trade.
---